OH/CCO recently launched a program with the goal of standardizing comprehensive hereditary cancer testing across Ontario. This includes a standardized gene list for all Clinical Diagnostics Laboratories performing this testing across the province, which has required the update of many existing NGS panels to add new genes. Three Ontario Genetics laboratories (CHEO, Kingston Health Sciences Center and Hamilton Health Sciences), previously using Roche SeqCap custom designed NGS panels, are now working together to share the design and validation of a new panel based on KAPA HyperCap Target Enrichment technology. This presentation will compare and contrast the results from the validation of this panel across the three laboratories and specifically evaluate the performance of the newly designed NGS hereditary cancer panel to detect copy number variants (CNVs) and other complex variants with a high-degree of accuracy.
Amanda Smith, PhD, DABMGG, FCCMG
Clinical Molecular Geneticist, CHEO
Assistant Professor of Pathology and Laboratory Medicine, University of Ottawa
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.